CHARLES TOWN, W. Va., Oct. 3 /PRNewswire-FirstCall/ -- In advance of releasing third quarter financial data, ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) noted today that each month in 2007 has produced nearly twice the sales revenues compared to the same month in 2006 for the Company. "Production costs are drastically down and our biggest problem is having enough space for the increase in inventory required by the leap in sales," reported CEO, David B Phillips.
ReBuilder Medical Technologies, Inc. correctly anticipated this increase in sales and a corresponding increase in equity sales during the third quarter. The company is meeting the needs of the cutting-edge treatment market for diabetic peripheral neuropathy and the special hygiene requirements of diabetics. "There are several complementary treatment modalities but none competes with the effectiveness of the ReBuilder System(R)," notes Dr. Phillips, "and our patients can tell the difference, some having gone from invalid status to recovering 100% of their pre-disease mobility in less than 90 days."
Daena Carter, the Company's CFO, points to record setting revenue on several days in September 2007, with $22,600.00, set on September 10, being the most recent. The previous record sales day was achieved just three days earlier on September 7, with approximately $22,000.00 in sales. Ms. Carter added, "We're becoming accustomed to seeing growth at this rate while we maintain quality for our customers and concurrent transparent reporting to our shareholders."
About ReBuilder Medical Technologies, Inc.:
ReBuilder Medical Technologies, Inc. is a manufacturer of medical devices and innovative technologies founded by world-renowned medical device inventor David B. Phillips, Ph.D. The company's flagship product is its FDA registered ReBuilder System(R), used for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) that depend on prescription drugs with powerful side effects, the ReBuilder System(R) is a portable, battery- powered medical product that provides a unique, non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.
ReBuilder Medical Technologies, Inc. also manufactures the Phillips Molluscum Treatment System(TM) for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses its proprietary form of micronized amorphous silver ions to disable the molluscum pathogen without side effects. The company is currently performing research and development on a number of other products as well.
ReBuilder Medical Technologies, Inc. is located in Charles Town, WV. CEO, Dr. David Phillips, Ph.D. is best known for inventing the very first infrared ear thermometer. Dr. Phillips also was responsible for the GST System, which is used for the early detection of breast cancer, and the AcuPen, a hand-held device that provides the benefits of acupuncture without the use of needles.
More information on ReBuilder Medical Technologies, Inc. and its products can be found at: http://www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward- looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
|SOURCE ReBuilder Medical Technologies, Inc.|
Copyright©2007 PR Newswire.
All rights reserved